Cognito Therapeutics has reached its enrolment goal for the randomised, sham-controlled HOPE Study investigating the Spectris AD system’s efficacy and safety in treating Alzheimer's disease. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback